A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health

Shane A. Landry, Siobhan Banks, Peter A. Cistulli, Garun S. Hamilton, Laure Héraud, Kristina Kairaitis, Steven Lubke, Sutapa Mukherjee, Teanau Roebuck, Joesph Soda, Darren Umbers, Shantha M. W. Rajaratnam, Darren Mansfield

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background and objective: Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Whether treatment of OSA improves cardiovascular risk remains controversial. Our aim was to determine a consensus opinion of key sleep medicine stakeholder groups as to the cardiovascular benefits of treating moderate–severe OSA. Methods: A multidisciplinary panel was assembled from representatives from the Australasian Sleep Association, Sleep Health Foundation, Australasian Sleep Technologists Association, the Sleep Health Foundation Business Council and the Sleep Disorders Australia patient support group. Three statements reflecting areas of controversy related to cardiovascular benefits of OSA treatment were created. A modified RAND/UCLA appropriateness methodology was applied determining the panel's level of consensus and agreement with each statement. Results: Voting results indicated the panel: (1) remained unsure whether moderate–severe OSA treatment improves rates of cardiovascular events/death, (2) agreed that moderate–severe OSA treatment improves blood pressure in patients with hypertension and (3) mostly agreed that moderate–severe OSA treatment improves left ventricular function in patients with heart failure. Consensus of opinion was achieved for statements (1) and (2), but was narrowly missed for statement (3). Conclusion: The panel believed that findings from large-scale randomized trials indicate that treatment of moderate–severe OSA has not been established to improve cardiovascular event or morbidity/mortality rates. Strong evidence supports the ability of treatment to reduce blood pressure. Whilst many panel members believed that treatment improves left ventricular function, some were uncertain of the clinical significance of this secondary endpoint measure derived from lesser quality evidence.

Original languageEnglish
Pages (from-to)376-381
Number of pages6
JournalRespirology
Volume24
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • blood pressure
  • cardiovascular diseases
  • sleep apnoea
  • treatment

Cite this

Landry, Shane A. ; Banks, Siobhan ; Cistulli, Peter A. ; Hamilton, Garun S. ; Héraud, Laure ; Kairaitis, Kristina ; Lubke, Steven ; Mukherjee, Sutapa ; Roebuck, Teanau ; Soda, Joesph ; Umbers, Darren ; Rajaratnam, Shantha M. W. ; Mansfield, Darren. / A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health. In: Respirology. 2019 ; Vol. 24, No. 4. pp. 376-381.
@article{d7476fc94ba9441b9ae90c55480ead83,
title = "A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health",
abstract = "Background and objective: Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Whether treatment of OSA improves cardiovascular risk remains controversial. Our aim was to determine a consensus opinion of key sleep medicine stakeholder groups as to the cardiovascular benefits of treating moderate–severe OSA. Methods: A multidisciplinary panel was assembled from representatives from the Australasian Sleep Association, Sleep Health Foundation, Australasian Sleep Technologists Association, the Sleep Health Foundation Business Council and the Sleep Disorders Australia patient support group. Three statements reflecting areas of controversy related to cardiovascular benefits of OSA treatment were created. A modified RAND/UCLA appropriateness methodology was applied determining the panel's level of consensus and agreement with each statement. Results: Voting results indicated the panel: (1) remained unsure whether moderate–severe OSA treatment improves rates of cardiovascular events/death, (2) agreed that moderate–severe OSA treatment improves blood pressure in patients with hypertension and (3) mostly agreed that moderate–severe OSA treatment improves left ventricular function in patients with heart failure. Consensus of opinion was achieved for statements (1) and (2), but was narrowly missed for statement (3). Conclusion: The panel believed that findings from large-scale randomized trials indicate that treatment of moderate–severe OSA has not been established to improve cardiovascular event or morbidity/mortality rates. Strong evidence supports the ability of treatment to reduce blood pressure. Whilst many panel members believed that treatment improves left ventricular function, some were uncertain of the clinical significance of this secondary endpoint measure derived from lesser quality evidence.",
keywords = "blood pressure, cardiovascular diseases, sleep apnoea, treatment",
author = "Landry, {Shane A.} and Siobhan Banks and Cistulli, {Peter A.} and Hamilton, {Garun S.} and Laure H{\'e}raud and Kristina Kairaitis and Steven Lubke and Sutapa Mukherjee and Teanau Roebuck and Joesph Soda and Darren Umbers and Rajaratnam, {Shantha M. W.} and Darren Mansfield",
year = "2019",
month = "4",
doi = "10.1111/resp.13413",
language = "English",
volume = "24",
pages = "376--381",
journal = "Respirology",
issn = "1323-7799",
publisher = "John Wiley & Sons",
number = "4",

}

A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health. / Landry, Shane A.; Banks, Siobhan; Cistulli, Peter A.; Hamilton, Garun S.; Héraud, Laure; Kairaitis, Kristina; Lubke, Steven; Mukherjee, Sutapa; Roebuck, Teanau; Soda, Joesph; Umbers, Darren; Rajaratnam, Shantha M. W.; Mansfield, Darren.

In: Respirology, Vol. 24, No. 4, 04.2019, p. 376-381.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health

AU - Landry, Shane A.

AU - Banks, Siobhan

AU - Cistulli, Peter A.

AU - Hamilton, Garun S.

AU - Héraud, Laure

AU - Kairaitis, Kristina

AU - Lubke, Steven

AU - Mukherjee, Sutapa

AU - Roebuck, Teanau

AU - Soda, Joesph

AU - Umbers, Darren

AU - Rajaratnam, Shantha M. W.

AU - Mansfield, Darren

PY - 2019/4

Y1 - 2019/4

N2 - Background and objective: Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Whether treatment of OSA improves cardiovascular risk remains controversial. Our aim was to determine a consensus opinion of key sleep medicine stakeholder groups as to the cardiovascular benefits of treating moderate–severe OSA. Methods: A multidisciplinary panel was assembled from representatives from the Australasian Sleep Association, Sleep Health Foundation, Australasian Sleep Technologists Association, the Sleep Health Foundation Business Council and the Sleep Disorders Australia patient support group. Three statements reflecting areas of controversy related to cardiovascular benefits of OSA treatment were created. A modified RAND/UCLA appropriateness methodology was applied determining the panel's level of consensus and agreement with each statement. Results: Voting results indicated the panel: (1) remained unsure whether moderate–severe OSA treatment improves rates of cardiovascular events/death, (2) agreed that moderate–severe OSA treatment improves blood pressure in patients with hypertension and (3) mostly agreed that moderate–severe OSA treatment improves left ventricular function in patients with heart failure. Consensus of opinion was achieved for statements (1) and (2), but was narrowly missed for statement (3). Conclusion: The panel believed that findings from large-scale randomized trials indicate that treatment of moderate–severe OSA has not been established to improve cardiovascular event or morbidity/mortality rates. Strong evidence supports the ability of treatment to reduce blood pressure. Whilst many panel members believed that treatment improves left ventricular function, some were uncertain of the clinical significance of this secondary endpoint measure derived from lesser quality evidence.

AB - Background and objective: Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Whether treatment of OSA improves cardiovascular risk remains controversial. Our aim was to determine a consensus opinion of key sleep medicine stakeholder groups as to the cardiovascular benefits of treating moderate–severe OSA. Methods: A multidisciplinary panel was assembled from representatives from the Australasian Sleep Association, Sleep Health Foundation, Australasian Sleep Technologists Association, the Sleep Health Foundation Business Council and the Sleep Disorders Australia patient support group. Three statements reflecting areas of controversy related to cardiovascular benefits of OSA treatment were created. A modified RAND/UCLA appropriateness methodology was applied determining the panel's level of consensus and agreement with each statement. Results: Voting results indicated the panel: (1) remained unsure whether moderate–severe OSA treatment improves rates of cardiovascular events/death, (2) agreed that moderate–severe OSA treatment improves blood pressure in patients with hypertension and (3) mostly agreed that moderate–severe OSA treatment improves left ventricular function in patients with heart failure. Consensus of opinion was achieved for statements (1) and (2), but was narrowly missed for statement (3). Conclusion: The panel believed that findings from large-scale randomized trials indicate that treatment of moderate–severe OSA has not been established to improve cardiovascular event or morbidity/mortality rates. Strong evidence supports the ability of treatment to reduce blood pressure. Whilst many panel members believed that treatment improves left ventricular function, some were uncertain of the clinical significance of this secondary endpoint measure derived from lesser quality evidence.

KW - blood pressure

KW - cardiovascular diseases

KW - sleep apnoea

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85054530584&partnerID=8YFLogxK

U2 - 10.1111/resp.13413

DO - 10.1111/resp.13413

M3 - Article

VL - 24

SP - 376

EP - 381

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 4

ER -